Should You Buy Artificial Intelligence (AI) Stocks In 2026?

Nvidia and Microsoft shares have stalled despite robust recent results—Nvidia revenue rose 62% year-over-year to $57 billion with net income up 65% to $31.9 billion, while Microsoft revenue grew 18% and operating income 24%—but lofty valuations (Nvidia P/E ~44; Microsoft P/E ~34) and cyclicality risks in AI infrastructure raise downside concerns. The piece argues Amazon (trailing P/E ~31), with dual growth engines in cloud and e-commerce and expanding AI partnerships (e.g., Anthropic), is a lower-risk, better-value play for 2026 as spending-driven supply-glut risks could pressure chip-driven beneficiaries like Nvidia.

Analysis

Market structure: The late-2025 stall concentrates downside on hyperscalers and chip makers (NVDA, to a lesser extent MSFT and ORCL) while relatively under-loved, diversified earners (AMZN) gain relative appeal. NVDA’s 62% Y/Y revenue growth and P/E ~44 imply high elasticity to capex cycles; if corporate AI spend slows by 20–30% YoY, NVDA EPS could compress double-digit percent. Supply/demand: history suggests an infrastructure buildout can flip to oversupply within 6–18 months — foundry lead times, channel inventory and OEM order cadence are the immediate supply signals to watch.

Risk assessment: Tail risks include a synchronized hyperscaler capex pullback, new US/China export controls on advanced accelerators, or a major customer (e.g., OpenAI) cutting spend — each could knock 30–50% off consensus forward earnings for incumbents. Near-term (days–weeks) expect volatility spikes and repricing around earnings; medium-term (3–12 months) order-book revisions; long-term (1–3 years) depends on durable AI adoption and pricing power. Hidden dependencies: concentration of GPU demand, Anthropic’s contract structure with AMZN, and margin mix shifts (data-center vs consumer) — monitor gross margin and backlog disclosures as leading indicators.

trade implications: Tactical overweight AMZN for 12–18 months because its P/E (~31) and dual engines (AWS + e‑commerce) buffer cyclicality; underweight or hedge NVDA exposure into 2026 given cyclic risk. Use relative-value pair trades (long AMZN / short NVDA) to remove market beta; size initial allocations small (1–3% net long). Options: buy 6–9 month NVDA puts (15–25% OTM) as insurance and consider AMZN long-dated calls or LEAPS if conviction >12 months; sell short-dated NVDA calls only if comfortable with assignment risk.

contrarian angles: The crowd may be over-penalizing NVDA for cyclical risk while under-discounting long-run structural demand — if AI workloads double over 24–36 months NVDA upside remains material. Conversely, AMZN’s lower multiple could re-rate only if AWS maintains >25% cloud growth and Anthropic wins material enterprise contracts — absent that, AMZN could underperform. Historical parallels: telecom capex busts (early 2000s) show large winners and losers; avoid binary thinking and size positions to event-risk (earnings, guidance) that will resolve over the next 1–3 quarters.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in AMZN sized as core-conviction (12–18 month horizon); accumulate on pullbacks of ≥8% within 30 days or if forward P/E drops below 28. Use a hard stop-loss at -12% from entry and trim to half at +20% realized gain.
• Initiate a defensive hedge against NVDA: buy 6–9 month NVDA puts 15–25% OTM sizing ~0.5–1% of portfolio notional (or equivalent options collar if long shares). Close or roll if NVDA issues revenue guidance that holds within ±5% of consensus or if implied volatility falls >30% from entry.
• Implement a pair trade: go long AMZN (1.5% notional) and short NVDA (1.0% notional) for 6–12 months to capture valuation dispersion; rebalance if NVDA forward revenue growth >40% or AMZN misses two consecutive quarters of AWS growth <20%.
• Reduce discretionary exposure to pure-play AI infra names (e.g., CRWV) by 50% versus Dec 2025 weights and reallocate to cash/IG bonds if credit spreads widen >50bps or tech sector volatility index (VXN/NVDA 30‑day IV proxy) rises >20%.